Depression
Major Depressive Disorder (MDD)
Major depressive disorder (MDD) is a common and serious mental health condition that can significantly affect a person’s daily functioning and overall well-being. According to the American Psychiatric Association (APA), depression is marked by a persistent low mood or loss of interest in activities, along with physical and cognitive symptoms that last for at least two weeks.
Why early treatment matters
Timely recognition and appropriate, evidence-based treatment are key to improving outcomes and reducing the risk of relapse. Providers play a critical role in identifying symptoms early and offering effective care tailored to each patient’s needs.
Recommended approach to care
The APA supports a stepped-care model, which means treatment is adjusted based on the severity of symptoms and patient preferences. This may include:
- Psychotherapy: Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT) are proven options.
- Medication: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed and effective for many patients.
Ongoing monitoring is essential, especially for treatment response, potential side effects, and suicide risk.
Treating children and adolescents
The American Academy of Pediatrics (AAP) recommends a similar multimodal approach for younger patients. Psychosocial interventions should be the foundation of care, with medication added when appropriate.
Personalized treatment planning
Effective care requires a personalized approach. Providers should consider factors such as the patient’s age, developmental stage, coexisting conditions, and personal values when developing treatment plans.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.)
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder (3rd ed.)
- American Academy of Pediatrics. (2018). Clinical Practice Guideline for the Diagnosis and Management of Depression in Children and Adolescents. Pediatrics, 141(3), e20174081.
| Pharmacologic class | Common brand names & formulations | Generic name |
| Selective Serotonin Reuptake Inhibitors (SSRIs) |
|
Citalopram |
| Selective Serotonin Reuptake Inhibitors (SSRIs) |
|
Escitalopram |
| Selective Serotonin Reuptake Inhibitors (SSRIs) |
|
Paroxetine |
| Selective Serotonin Reuptake Inhibitors (SSRIs) |
|
Fluoxetine |
| Selective Serotonin Reuptake Inhibitors (SSRIs) |
|
Sertraline |
| Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) |
|
Duloxetine |
| Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) |
|
Venlafaxine |
| Atypical Antidepressants |
|
Bupropion |
| Atypical Antidepressants |
|
Mirtazapine |
| Serotonin modulators |
|
Vilazodone |
| Serotonin modulators |
|
Vortioxetine |
Want more?
Find help for more behavioral health topics in our provider toolkit.
You are leaving the WellSense website
You are now leaving the WellSense website, and are being connected to a third party web site. Please note that WellSense is not responsible for the information, content or product(s) found on third party web sites.
By accessing the noted link you will be leaving our website and entering a website hosted by another party. Please be advised that you will no longer be subject to, or under the protection of, our privacy and security policies. We encourage you to read and evaluate the privacy and security policies of the site you are entering, which may be different than ours.